论文部分内容阅读
目的观察前列地尔与缬沙坦联合应用治疗早期糖尿病肾病的临床效果。方法将60例确诊早期糖尿病肾病的患者随机分为实验组和对照组,实验组予前列地尔静脉滴注联合缬沙坦口服,对照组单用缬沙坦,两组均给予糖尿病基础治疗,比较两组治疗前后血压及尿蛋白排出量的变化情况。结果两组患者血压均控制理想,24 h尿蛋白量均有下降,以实验组下降最明显,两组间差异有统计学意义(P<0.05)。结论前列地尔与缬沙坦联合应用控制早期糖尿病肾病患者尿蛋白排出量及血压的效果明显优于缬沙坦单药应用的效果,两者可发挥协同作用,更大程度地保护肾脏,延缓肾功能恶化。
Objective To observe the clinical effect of alprostadil combined with valsartan in the treatment of early diabetic nephropathy. Methods Sixty patients diagnosed with early diabetic nephropathy were randomly divided into experimental group and control group. The experimental group was treated with alprostadil plus valsartan intravenously, the control group with valsartan alone. Both groups were given basic treatment of diabetes, The changes of blood pressure and urinary protein excretion before and after treatment were compared between the two groups. Results The blood pressure in both groups was well controlled and the proteinuria in 24 h decreased. The most obvious drop was in the experimental group, with significant difference between the two groups (P <0.05). Conclusion The combination of alprostadil and valsartan in the control of urinary protein excretion and blood pressure in patients with early diabetic nephropathy is significantly better than that of valsartan monotherapy. Both of them can play a synergistic role to protect the kidneys to a greater extent and delay Renal deterioration.